Cancer cachexia: Malignant inflammation, tumorkines, and metabolic mayhem

Trends in Endocrinology and Metabolism

Volumn 24, Issue 4, 2013, Pages 174-183

  Tsoli, Maria ^a   Robertson, Graham ^a  

^a Department of Microbiology and Infectious Diseases   (Australia)

Author keywords

Brown adipose tissue; Cancer cachexia; Insulin resistance; Lipid metabolism; Tumorkines; White adipose tissue

Indexed keywords

CYTOKINE; INSULIN; INTERLEUKIN 6; LIPID;

ADIPOSE TISSUE; BROWN ADIPOSE TISSUE; CACHEXIA; CANCER PATIENT; CYTOKINE PRODUCTION; ENERGY BALANCE; HUMAN; INFLAMMATION; INSULIN RESISTANCE; LIPID STORAGE; LIPOLYSIS; METABOLIC REGULATION; MOLECULAR INTERACTION; NONHUMAN; OBESITY; PREVALENCE; PRIORITY JOURNAL; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; THERMOGENESIS; TREATMENT OUTCOME; WASTING SYNDROME; WHITE ADIPOSE TISSUE;

ANIMALS; CACHEXIA; ENERGY METABOLISM; HUMANS; INFLAMMATION; NEOPLASMS;

EID: 84877919797     PISSN: 10432760     EISSN: 18793061     Source Type: Journal    
DOI: 10.1016/j.tem.2012.10.006     Document Type: Review

References (100)

1. Dewys W.D., et al. Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. Am. J. Med. 1980, 69:491-497.
2. Deans C., Wigmore S.J. Systemic inflammation, cachexia and prognosis in patients with cancer. Curr. Opin. Clin. Nutr. Metab. Care 2005, 8:265-269.
3. Tan B.H., Fearon K.C. Cachexia: prevalence and impact in medicine. Curr. Opin. Clin. Nutr. Metab. Care 2008, 11:400-407.
4. Chawla A., et al. Macrophage-mediated inflammation in metabolic disease. Nat. Rev. Immunol. 2011, 11:738-749.
5. Donath M.Y., Shoelson S.E. Type 2 diabetes as an inflammatory disease. Nat. Rev. Immunol. 2011, 11:98-107.
6. Lumeng C.N., Saltiel A.R. Inflammatory links between obesity and metabolic disease. J. Clin. Invest. 2011, 121:2111-2117.
7. Samuel V.T., Shulman G.I. Mechanisms for insulin resistance: common threads and missing links. Cell 2012, 148:852-871.
8. Glass C.K., Olefsky J.M. Inflammation and lipid signaling in the etiology of insulin resistance. Cell Metab. 2012, 15:635-645.
9. Chavez J.A., Summers S.A. A ceramide-centric view of insulin resistance. Cell Metab. 2012, 15:585-594.
10. Fearon K.C.H., et al. Cancer cachexia: mediators, signaling, and metabolic pathways. Cell Metab. 2012, 16:153-166.
11. Dodson S., et al. Muscle wasting in cancer cachexia: clinical implications, diagnosis, and emerging treatment strategies. Annu. Rev. Med. 2011, 62:265-279.
12. Carson J.A., Baltgalvis K.A. Interleukin 6 as a key regulator of muscle mass during cachexia. Exerc. Sport Sci. Rev. 2010, 38:168-176.
13. Zhou X., et al. Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival. Cell 2010, 142:531-543.
14. Benny-Klimek M.E., et al. Acute inhibition of myostatin-family proteins preserves skeletal muscle in mouse models of cancer cachexia. Biochem. Biophys. Res. Commun. 2010, 391:1548-1554.
15. Murphy K.T., et al. Antibody-directed myostatin inhibition enhances muscle mass and function in tumor-bearing mice. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2011, 301:R716-R726.
16. Bonetto A., et al. JAK/STAT3 pathway inhibition blocks skeletal muscle wasting downstream of IL-6 in experimental cancer cachexia. Am. J. Physiol. Endocrinol. Metab. 2012, 303:E410-E421.
17. Blum D., et al. Cancer cachexia: a systematic literature review of items and domains associated with involuntary weight loss in cancer. Crit. Rev. Oncol. Hematol. 2011, 80:114-144.
18. Ben-Neriah Y., Karin M. Inflammation meets cancer, with NF-κB as the matchmaker. Nat. Immunol. 2011, 12:715-723.
19. Balkwill F.R., Mantovani A. Cancer-related inflammation: common themes and therapeutic opportunities. Semin. Cancer Biol. 2012, 22:33-40.
20. Grivennikov S.I., et al. Immunity, inflammation, and cancer. Cell 2010, 140:883-899.
21. Proctor M.J., et al. An inflammation-based prognostic score (mGPS) predicts cancer survival independent of tumour site: a Glasgow Inflammation Outcome Study. Br. J. Cancer 2011, 104:726-734.
22. Richards C.H., et al. The relationships between body composition and the systemic inflammatory responsein patients with primary inoperable colorectal cancer. PLoS ONE 2012, 7:e41883.
23. Galic S., et al. Adipose tissue as an endocrine organ. Mol. Cell. Endocrinol. 2010, 16:129-139.
24. Rydén M., et al. Lipolysis - not inflammation, cell death, or lipogenesis - is involved in adipose tissue loss in cancer cachexia. Cancer 2008, 113:1695-1704.
25. Kosteli A., et al. Weight loss and lipolysis promote a dynamic immune response in murine adipose tissue. J. Clin. Invest. 2010, 120:3466-3479.
26. Prado C.M., et al. Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study. Lancet Oncol. 2008, 9. 629-623.
27. Tan B.H., et al. Sarcopenia in an overweight or obese patient is an adverse prognostic factor in pancreatic cancer. Clin. Cancer Res. 2009, 15:6973-6979.
28. Parsons H.A., et al. Body composition, symptoms, and survival in advanced cancer patients referred to a phase I service. PLoS ONE 2012, 7:e29330.
29. Fouladiun M., et al. Body composition and time course changes in regional distribution of fat and lean tissue in unselected cancer patients on palliative care - correlations with food intake, metabolism, exercise capacity, and hormones. Cancer 2005, 103:2189-2198.
30. Baracos V.E., et al. Body composition in patients with non-small cell lung cancer: a contemporary view of cancer cachexia with the use of computed tomography image analysis. Am. J. Clin. Nutr. 2010, 91:1133S-1137S.
31. Murphy R.A., et al. Loss of adipose tissue and plasma phospholipids: relationship to survival in advanced cancer patients. Clin. Nutr. 2010, 29:482-487.
32. Lieffers J.R., et al. A viscerally driven cachexia syndrome in patients with advanced colorectal cancer: contributions of organ and tumor mass to whole-body energy demands. Am. J. Clin. Nutr. 2009, 89:1173-1179.
33. Laurencikiene J., et al. Evidence for an important role of CIDEA in human cancer cachexia. Cancer Res. 2008, 68:9247-9254.
34. Agustsson T., et al. Mechanism of increased lipolysis in cancer cachexia. Cancer Res. 2007, 67:5531-5537.
35. Haugen F., et al. Altered expression of genes in adipose tissues associated with reduced fat mass in patients with pancreatic cancer. Arch. Physiol. Biochem. 2011, 117:78-87.
36. Dahlman I., et al. Adipose tissue pathways involved in weight loss of cancer cachexia. Br. J. Cancer 2010, 102:1541-1548.
37. Das S.K., et al. Adipose triglyceride lipase contributes to cancer-associated cachexia. Science 2011, 333:233-238.
38. Fearon K.C. Cancer cachexia and fat-muscle physiology. N. Engl. J. Med. 2011, 365:565-567.
39. Arner P. Lipases in cachexia. Science 2011, 333:163-164.
40. Stephens N.A., et al. Intramyocellular lipid droplets increase with progression of cachexia in cancer patients. J. Cachexia Sarcopenia Muscle 2011, 2:111-117.
41. Batista M.L., et al. Adipose tissue inflammation and cancer cachexia: possible role of nuclear transcription factors. Cytokine 2012, 57:9-16.
42. Bing C., et al. Adipose atrophy in cancer cachexia: morphologic and molecular analysis of adipose tissue in tumour-bearing mice. Br. J. Cancer 2006, 95:1028-1037.
43. Lee P., et al. A critical appraisal of the prevalence and metabolic significance of brown adipose tissue in adult humans. Am. J. Physiol. Endocrinol. Metab. 2010, 299:E601-E606.
44. Nedergaard J., Cannon B. The changed metabolic world of human brown adipose tissue: therapeutic visions. Cell Metab. 2010, 11:268-272.
45. Lee P., et al. High prevalence of brown adipose tissue in adult humans. J. Clin. Endocrinol. Metab. 2011, 96:2450-2455.
46. Arruda A.P., et al. Hypothalamic actions of tumor necrosis factor alpha provide the thermogenic core for the wastage syndrome in cachexia. Endocrinology 2010, 151:683-694.
47. Li G., et al. Induction of uncoupling protein 1 by central IL-6 gene delivery is dependent on sympathetic innervation of brown adipose tissue and underlies one mechanism of body weight reduction in rats. Neuroscience 2002, 115:879-889.
48. Tsoli M., et al. Activation of thermogenesis in brown adipose tissue and dysregulated lipid metabolism associated with cancer cachexia in mice. Cancer Res. 2012, 72:4372-4382.
49. Nilsberth C., et al. The role of interleukin-6 in lipopolysaccharide-induced fever by mechanisms independent of prostaglandin E2. Endocrinology 2009, 150:1850-1860.
50. Sharma R., et al. Inflammatory (B) symptoms are independent predictors of myelosuppression from chemotherapy in non-Hodgkin lymphoma (NHL) patients--analysis of data from a British National Lymphoma Investigation phase III trial comparing CHOP to PMitCEBO. BMC Cancer 2009, 9:153.
51. Falconer J.S., et al. Cytokines, the acute-phase response, and resting energy expenditure in cachectic patients with pancreatic cancer. Ann. Surg. 1994, 219:325-331.
52. Simons J.P., et al. Weight loss and low body cell mass in males with lung cancer: relationship with systemic inflammation, acute-phase response, resting energy expenditure, and catabolic and anabolic hormones. Clin. Sci. (Lond.) 1999, 97:215-222.
53. Fearon K.C., et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 2011, 12:489-495.
54. Stephens N.A., et al. Using transcriptomics to identify and validate novel biomarkers of human skeletal muscle cancer cachexia. Genome Med. 2010, 2:1.
55. Gallagher I.J., et al. Suppression of skeletal muscle turnover in cancer cachexia: evidence from the transcriptome in sequential human muscle biopsies. Clin. Cancer Res. 2012, 18:2817-2827.
56. Bonetto A., et al. STAT3 activation in skeletal muscle links muscle wasting and the acute phase response in cancer cachexia. PLoS ONE 2011, 6:e22538.
57. Peters S.J., et al. Dose-dependent effects of leucine supplementation on preservation of muscle mass in cancer cachectic mice. Oncol. Rep. 2011, 26. 247-245.
58. Cassolla P., et al. Changes in blood metabolic parameters during the development of Walker-256 tumour-induced cachexia in rats are not caused by decreased food intake. Cell Biochem. Funct. 2011, 30:265-270.
59. De Larichaudy J., et al. TNF-α- and tumor-induced skeletal muscle atrophy involves sphingolipid metabolism. Skelet. Muscle 2012, 2:2.
60. Penet M.F., et al. Metabolic signatures imaged in cancer-induced cachexia. Cancer Res. 2011, 71:6948-6956.
61. Zhang D., et al. Association of IL-6 gene polymorphisms with cachexia susceptibility and survival time of patients with pancreatic cancer. Ann. Clin. Lab. Sci. 2008, 38:113-119.
62. Deans D.A., et al. Cancer cachexia is associated with the IL10-1082 gene promoter polymorphism in patients with gastroesophageal malignancy. Am. J. Clin. Nutr. 2009, 89:1164-1172.
63. Sun F., et al. Association of interleukin-10 gene polymorphism with cachexia in Chinese patients with gastric cancer. Ann. Clin. Lab. Sci. 2010, 40:149-155.
64. Bo S., et al. Association of interleukin-8 gene polymorphism with cachexia from patients with gastric cancer. J. Interferon Cytokine Res. 2010, 30:9-14.
65. Jatoi A., et al. The cancer anorexia/weight loss syndrome: exploring associations with single nucleotide polymorphisms (SNPs) of inflammatory cytokines in patients with non-small cell lung cancer. Support Care Cancer 2010, 18:1299-1304.
66. Tan B.H., et al. Identification of possible genetic polymorphisms involved in cancer cachexia: a systematic review. J. Genet. 2011, 90:165-177.
67. Solheim T.S., et al. Is there a genetic cause for cancer cachexia? - a clinical validation study in 1797 patients. Br. J. Cancer 2011, 105:1244-1251.
68. Tan B.H., et al. P-selectin genotype is associated with the development of cancer cachexia. EMBO Mol. Med. 2012, 4:462-471.
69. Honors M.A., Kinzig K.P. The role of insulin resistance in the development of muscle wasting during cancer cachexia. J. Cachexia Sarcopenia Muscle 2012, 3:5-11.
70. Winter A., et al. Normal protein anabolic response to hyperaminoacidemia in insulin-resistant patients with lung cancer. Clin. Nutr. 2012, 31:765-773.
71. Asp M.L., et al. Evidence for the contribution of insulin resistance to the development of cachexia in tumor-bearing mice. Int. J. Cancer 2010, 126:756-763.
72. Asp M.L., et al. Rosiglitazone delayed weight loss and anorexia while attenuating adipose depletion in mice with cancer cachexia. Cancer Biol. Ther. 2011, 12:957-965.
73. Pedersen B.K., Febbraio M.A. Muscles, exercise and obesity: skeletal muscle as a secretory organ. Nat. Rev. Endocrinol. 2012, 8:457-468.
74. Trayhurn P., et al. Secreted proteins from adipose tissue and skeletal muscle - adipokines, myokines and adipose/muscle cross-talk. Arch. Physiol. Biochem. 2011, 117:47-56.
75. Franckhauser S., et al. Overexpression of Il6 leads to hyperinsulinaemia, liver inflammation and reduced body weight in mice. Diabetologia 2008, 51:1306-1316.
76. Ellingsgaard H., et al. Interleukin-6 enhances insulin secretion by increasing glucagon-like peptide-1 secretion from L cells and alpha cells. Nat. Med. 2011, 17:1481-1489.
77. Allen T.L., et al. IL-6 muscles in on the gut and pancreas to enhance insulin secretion. Cell Metab. 2012, 15:8-9.
78. Murphy K.T., Lynch G.S. Editorial update on emerging drugs for cancer cachexia. Expert Opin. Emerg. Drugs 2012, 17:5-9.
79. Argilés J.M., et al. Consensus on cachexia definitions. J. Am. Med. Dir. Assoc. 2010, 11:229-230.
80. Evans W.J., et al. Cachexia: a new definition. Clin. Nutr. 2008, 27:793-799.
81. Bauer J., et al. Important aspects of nutrition in children with cancer. Adv. Nutr. 2011, 2:67-77.
82. WHO Child Growth Standards: Length/Height-For-Age, Weight-For-Age, Weight-For-Length, Weight-For-Height and Body Mass Index-For-Age: Methods and Development 2006, WHO Multicentre Growth Reference Study Group, World Health Organization.
83. Ladas E.J., et al. A multidisciplinary review of nutrition considerations in the pediatric oncology population: a perspective from children's oncology group. Nutr. Clin. Pract. 2005, 20:377-393.
84. Brinksma A., et al. Malnutrition in childhood cancer patients: a review on its prevalence and possible causes. Crit. Rev. Oncol. Hematol. 2012, 83:249-275.
85. Drubach L.A., et al. Pediatric brown adipose tissue: detection, epidemiology, and differences from adults. J. Pediatr. 2011, 159:939-944.
86. Chalfant J.S., et al. Inverse association between brown adipose tissue activation and white adipose tissue accumulation in successfully treated pediatric malignancy. Am. J. Clin. Nutr. 2012, 95:1144-1149.
87. Petersen E.W., et al. Acute IL-6 treatment increases fatty acid turnover in elderly humans in vivo and in tissue culture in vitro. Am. J. Physiol. Endocrinol. Metab. 2005, 288:E155-E162.
88. Wolsk E., et al. IL-6 selectively stimulates fat metabolism in human skeletal muscle. Am. J. Physiol. Endocrinol. Metab. 2010, 299:E832-E840.
89. Ji C., et al. IL-6 induces lipolysis and mitochondrial dysfunction, but does not affect insulin-mediated glucose transport in 3T3-L1 adipocytes. J. Bioenerg. Biomembr. 2011, 43:367-375.
90. Bordicchia M., et al. Cardiac natriuretic peptides act via p38 MAPK to induce the brown fat thermogenic program in mouse and human adipocytes. J. Clin. Invest. 2012, 122:1022-1036.
91. Scheller J., et al. The pro- and anti-inflammatory properties of the cytokine interleukin-6. Biochim. Biophys. Acta 2011, 1813:878-888.
92. Straub R.H., et al. Energy regulation and neuroendocrine-immune control in chronic inflammatory diseases. J. Intern. Med. 2010, 267:543-560.
93. Seruga B., et al. Cytokines and their relationship to the symptoms and outcome of cancer. Nat. Rev. Cancer 2008, 8:887-889.
94. Pedersen B.K., Febbraio M.A. Muscle as an endocrine organ: focus on muscle-derived interleukin-6. Physiol. Rev. 2008, 88:1379-1406.
95. Gibbs J.E., et al. The nuclear receptor REV-ERBα mediates circadian regulation of innate immunity through selective regulation of inflammatory cytokines. Proc. Natl. Acad. Sci. U.S.A. 2012, 109:582-587.
96. Frontini A., Cinti S. Distribution and development of brown adipocytes in the murine and human adipose tissue. Cell Metab. 2010, 11:253-256.
97. Wu J., et al. Beige adipocytes are a distinct type of thermogenic fat cell in mouse and human. Cell 2012, 150:366-376.
98. Zechner R., et al. Fat signals - lipases and lipolysis in lipid metabolism and signaling. Cell Metab. 2012, 15:279-291.
99. Whittle A.J., et al. Using brown adipose tissue to treat obesity - the central issue. Trends Mol. Med. 2011, 17:405-411.
100. Bartelt A., et al. Brown adipose tissue activity controls triglyceride clearance. Nat. Med. 2011, 17:200-205.